After a successful fund raising campaign, local startup company Estrigenix has engaged the MIDD to conduct pre-clinical characterization of their lead compounds. Estrigenix Therapeutics was formed in 2018 as a spin out from a collaboration research of three Milwaukee area university scientists: Drs. Donaldson, Frick and Sem. Funds were received from CU Ventures and affiliated Concordia Angel Network accelerating drug development at the Innovation Campus and at UWM.